Investigational Drug Information for chiauranib
✉ Email this page to a colleague
What is the drug development status for chiauranib?
chiauranib is an investigational drug.
There have been 16 clinical trials for chiauranib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2021.
The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Medelis Inc., and H & J CRO International, Inc.
There is one US patent protecting this investigational drug.
Summary for chiauranib
| US Patents | 1 |
| International Patents | 0 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2021-07-01) |
| Vendors | 28 |
Recent Clinical Trials for chiauranib
| Title | Sponsor | Phase |
|---|---|---|
| Anti-PD-1 and CTLA-4 Bispecific Antibody AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | Chipscreen Biosciences, Ltd. | Phase 1/Phase 2 |
| Anti-PD-1 and CTLA-4 Bispecific Antibody AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | Akeso | Phase 1/Phase 2 |
| Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) | Chipscreen Biosciences, Ltd. | Phase 2 |
Clinical Trial Summary for chiauranib
Top disease conditions for chiauranib
Top clinical trial sponsors for chiauranib
US Patents for chiauranib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| chiauranib | ⤷ Sign Up | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
